Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…Directional steering in subthalamic deep brain stimulation for Parkinson’s disease: the Berlin experience
Objective: To review the use of directional current steering in a Berlin cohort implanted with segmented leads between 2016-2019. Background: The dorsolateral area of the subthalamic…DOPAMINERGIC AND NON-DOPAMINERGIC TREATMENT AFTER DEEP BRAIN STIMULATION (DBS) IN PARKINSON DISEASE (PD). IMPORTANCE OF NON MOTOR SYMPTOMS (NMS)
Objective: To analyse global pharmacological adjustment after Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) patients, and secondarily its relation with Non Motor Symptoms (NMS).…Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension
Objective: To describe the real-world characteristics of advanced Parkinson’s disease (APD) patients initiating carbidopa/levodopa enteral suspension (CLES) therapy in USA Background: CLES is an FDA…Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…Determinants of exercise behavior in Parkinson’s disease patients: Self-confidence in balance and fatigue play the pivotal role.
Objective: To identify the determinants of the exercise behavior in PD patients Background: The exercise is promising treatment for Parkinson’s disease (PD) which has been…AMP PD: Collaborating in the discovery of biomarkers to accelerate the development of therapies for Parkinson’s disease
Objective: The Accelerating Medicines Partnership in Parkinson’s Disease (AMP PD; https://amp-pd.org) aims to identify and validate diagnostic, prognostic, and progression biomarkers for Parkinson’s Disease (PD).…Initial longitudinal analyses of objectively assessed cognitive functional abilities in a cohort with Parkinson’s disease
Objective: Detect the earliest changes in cognitively demanding activities of daily living in Parkinson's disease (PD) and determine their relationship with changes in global cognition…White matter and cognition in Parkinson’s disease
Objective: Examine whether a recently developed MRI biomarker intended to assess cerebrovascular small vessel disease, peak width of skeletonized mean diffusivity (PSMD)[1], predicts cognitive decline…Genotypic and phenotypic spectrum of PINK-1 associated parkinsonism in 44 mutation carriers from 11 Tunisian families
Objective: To characterize the family history and clinical features of mutations of the PINK-1 gene in a cohort of Tunisian patients with Parkinson disease (P.D)…
- « Previous Page
- 1
- …
- 325
- 326
- 327
- 328
- 329
- …
- 338
- Next Page »